Press Release
InnoCare Releases 2020 Annual Results and Business Highlights
26 Mar, 2021
82
3345
InnoCare to Hold 2021 R&D Day on April 15, 2021
15 Mar, 2021
48
InnoCare to Hold 2021 R&D Day on April 15, 2021
3332
InnoCare to Host 2020 Full Year Earnings Call on March 29, 2021
11 Mar, 2021
45
InnoCare to Host 2020 Full Year Earnings Call on March 29, 2021
3327
InnoCare Appoints Dr. Sean Zhang as Chief Medical Officer
01 Mar, 2021
62
3318
InnoCare Announces Approval of Orelabrutinib in Combination with R-CHOP as First-Line Therapy for Mantle Cell Lymphoma in China
05 Feb, 2021
115
Beijing, Feb. 5, 2021 —— InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that China National Medical Products Administration (NMPA) has approved the clinical trial of Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib in combination with R-CHOP for previously untreated patients with mantle cell lymphoma (MCL).
3306